Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19315079 | S-BETA-HYDROXYBUTYRATE ESTERS FOR IMPROVING METABOLIC FUNCTION | August 2025 | January 2026 | Allow | 5 | 1 | 0 | No | No |
| 19207954 | SHORT CHAIN FATTY ACID COMPOUNDS AND USES THEREOF | May 2025 | December 2025 | Allow | 7 | 0 | 0 | No | No |
| 18892950 | REDUCING THE RISK OF VIRAL INFECTION DUE TO VIRAL CONTAMINATED FEED | September 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18807247 | SYSTEM AND METHOD FOR TRIGLYCERIDE MANUFACTURE | August 2024 | June 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18776474 | MONOGLYCERIDE USE IN ANIMALS | July 2024 | October 2025 | Allow | 14 | 1 | 0 | No | No |
| 18774065 | MODULAR, MOBILE, AND AUTOMATED SOLVENT EXTRACTION AND DISTILLATION SYSTEMS, AND METHODS OF USING THE SAME | July 2024 | August 2025 | Allow | 13 | 1 | 0 | No | No |
| 18745509 | COMPOSITIONS AND METHODS FOR MODULATING EQUINE FATTY ACID PROFILES | June 2024 | September 2025 | Allow | 15 | 1 | 0 | No | No |
| 18610897 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | March 2024 | June 2025 | Allow | 15 | 2 | 1 | Yes | No |
| 18577214 | NOVEL COMBINATORIAL ANTITUMOR TREATMENT METHODS AND RELATED COMPOSITIONS, KITS, AND SYSTEMS | January 2024 | February 2025 | Allow | 14 | 1 | 0 | No | No |
| 18537355 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF INFLAMMATORY, DEGENERATIVE, AND NEURODEGENERATIVE DISEASES | December 2023 | October 2025 | Allow | 23 | 2 | 0 | No | No |
| 18515464 | COMPOSITIONS AND METHODS FOR SOLIDIFIED FERMENTED ANIMAL FEED | November 2023 | February 2025 | Allow | 15 | 0 | 0 | No | No |
| 18265491 | METHOD FOR PREPARING ACRYLIC ACID | June 2023 | December 2025 | Allow | 31 | 0 | 0 | No | No |
| 18038031 | PROCESS FOR PRODUCING ISOCYANATES | May 2023 | December 2025 | Allow | 30 | 0 | 0 | No | No |
| 18250587 | PRODUCTION OF 2,2,4,4-TETRAMETHYLCYCLOBUTANE-1,3-DIOL FROM ISOBUTANOL USING A HOMOGENEOUS CATALYST | April 2023 | October 2025 | Allow | 30 | 0 | 0 | No | No |
| 18249984 | A METHOD FOR THE PREPARATION OF 1,2-PROPANEDIOL | April 2023 | October 2025 | Allow | 30 | 0 | 0 | No | No |
| 18249982 | A METHOD FOR THE PREPARATION OF 1,2-PROPANEDIOL | April 2023 | February 2026 | Allow | 34 | 1 | 0 | No | No |
| 18249695 | A METHOD FOR THE PREPARATION OF 1,2-PROPANEDIOL | April 2023 | October 2025 | Allow | 30 | 0 | 0 | No | No |
| 18249729 | A PROCESS FOR PREPARING 1,2-PROPANEDIOL FROM PROPANE | April 2023 | September 2025 | Allow | 29 | 0 | 0 | No | No |
| 18249660 | A METHOD FOR THE PREPARATION OF 1,2-PROPANEDIOL | April 2023 | September 2025 | Allow | 29 | 0 | 0 | No | No |
| 18249724 | METHOD FOR THE PREPARATION OF 1,2-PROPANEDIOL | April 2023 | October 2025 | Allow | 30 | 0 | 0 | No | No |
| 18296363 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | April 2023 | October 2025 | Allow | 31 | 0 | 0 | No | No |
| 18130439 | PROCESS FOR SYNTHESIS OF FLUORINATED OLEFINS | April 2023 | September 2025 | Allow | 29 | 0 | 0 | No | No |
| 18028001 | A PROCESS FOR THE SYNTHESIS OF ANTHRANILIC ACID/AMIDE COMPOUNDS AND INTERMEDIATES THEREOF | March 2023 | February 2026 | Allow | 35 | 1 | 0 | No | No |
| 18026610 | A PROCESS FOR THE SYNTHESIS OF ANTHRANILIC ACID/AMIDE COMPOUNDS AND INTERMEDIATES THEREOF | March 2023 | February 2026 | Allow | 35 | 1 | 0 | No | No |
| 18025527 | METHOD FOR PRODUCING COMPOUND | March 2023 | February 2026 | Allow | 36 | 1 | 0 | No | No |
| 18023747 | PROCESS FOR PRODUCING ISOCYANATES | February 2023 | August 2025 | Allow | 30 | 0 | 0 | No | No |
| 18111018 | METHOD OF PRODUCING ADIPIC ACID | February 2023 | July 2025 | Allow | 29 | 0 | 0 | No | No |
| 18110060 | METHOD FOR PURIFYING ACRYLIC ACID ESTER COMPOUND | February 2023 | November 2025 | Allow | 33 | 0 | 0 | No | No |
| 18040999 | ISOBUTANOL PRODUCTION PROCESS | February 2023 | August 2025 | Allow | 30 | 0 | 0 | No | No |
| 18040992 | ETHANOL CONVERSION TO ISOBUTANOL | February 2023 | July 2025 | Allow | 29 | 0 | 0 | No | No |
| 18018585 | DEVICE AND METHOD FOR PRODUCING METHANOL FROM CARBON DIOXIDE | January 2023 | August 2025 | Allow | 31 | 0 | 0 | No | No |
| 18161619 | REDUCING THE RISK OF VIRAL INFECTION DUE TO VIRAL CONTAMINATED FEED | January 2023 | July 2025 | Allow | 30 | 1 | 0 | No | No |
| 18016198 | METHOD FOR PREPARING ESTER-BASED COMPOSITION | January 2023 | February 2026 | Allow | 37 | 1 | 0 | Yes | No |
| 18003460 | COLORLESS MONOCHLOROACETIC ACID AND THE METHOD OF PREPARATION THEREOF | December 2022 | January 2026 | Allow | 37 | 1 | 0 | Yes | No |
| 17791561 | METHOD FOR PREPARING ISOPROPYL ALCOHOL | December 2022 | July 2025 | Allow | 36 | 0 | 0 | No | No |
| 18008757 | Process for Recovering Oxidation By-Products | December 2022 | January 2026 | Allow | 37 | 1 | 0 | No | No |
| 18008312 | LIMITING ACETIC ACID PRODUCTION IN ETHANE ODH PROCESS | December 2022 | January 2025 | Allow | 26 | 0 | 0 | No | No |
| 18000539 | PROCESS FOR PURIFYING A MIXTURE OF DIOLS | December 2022 | December 2025 | Allow | 37 | 2 | 0 | No | No |
| 17928567 | PRODUCTION AND PURIFICATION OF ACETIC ACID | November 2022 | December 2025 | Allow | 37 | 1 | 0 | No | No |
| 17926301 | AGENT FOR INDUCING REGRESSION OF TRIGLYCERIDE DEPOSIT ATHEROSCLEROSIS | November 2022 | January 2026 | Allow | 38 | 1 | 0 | No | No |
| 17926107 | METHOD FOR PREPARING ACRYLIC ACID FROM BETA-PROPIOLACTONE | November 2022 | July 2025 | Allow | 32 | 0 | 0 | No | No |
| 17925812 | Use of 4-Phenylbutyric Acid and/or 3-Phenylbutyric Acid and/or 2-Phenylbutyric Acid in Preventing and Treating Cryptogamic Diseases | November 2022 | February 2026 | Abandon | 39 | 2 | 0 | No | No |
| 17998891 | MCT FORMULATIONS FOR IMPROVING COGNITIVE FUNCTIONS | November 2022 | November 2025 | Allow | 36 | 1 | 0 | No | No |
| 17924373 | SYSTEM AND METHOD FOR CONTINUOUSLY PRODUCING DIETHYL METHYLPHOSPHONITE | November 2022 | October 2025 | Allow | 35 | 1 | 0 | No | No |
| 17918339 | PERSONAL CARE COMPOSITION WITH VISUALLY DISTINCT AQUEOUS AND OIL PHASE | October 2022 | August 2025 | Allow | 34 | 0 | 0 | No | No |
| 17907368 | NOVEL CATIONIC LIPID HAVING CYSTINE SKELETON | September 2022 | March 2026 | Allow | 42 | 0 | 1 | No | No |
| 17914086 | METHOD OF FRACTIONATION OF FATTY ACIDS WITH A DIFFERENCE OF TWO CARBONS BY MOLECULAR DISTILLATION | September 2022 | November 2025 | Allow | 38 | 1 | 0 | No | No |
| 17800758 | PROCESS FOR MAKING SOLID METHYLGLYCINE DIACETATE ALKALI METAL SALTS | August 2022 | October 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17758759 | TREATMENT OF LATE-ONSET NEURODEGENERATIVE DISEASES IN HETEROZYGOUS NPC1 GENE MUTATION CARRIERS | July 2022 | December 2025 | Allow | 41 | 1 | 0 | No | No |
| 17787611 | CO-CRYSTAL OF KETOPROFEN AND ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17787934 | EDIBLE OIL/FAT IN WHICH CONTENT OF GLYCIDOL AND GLYCIDOL FATTY ACID ESTER ARE REDUCED, AND METHOD FOR MANUFACTURING SAID EDIBLE OIL/FAT | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17787519 | A TOPICAL ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITION COMPRISING ZILEUTON | June 2022 | November 2025 | Allow | 41 | 1 | 0 | No | No |
| 17787541 | ANHYDROUS COMPOSITION FOR CARING FOR KERATIN MATERIALS | June 2022 | September 2025 | Allow | 39 | 1 | 0 | No | No |
| 17783770 | BIOMOLECULE FOR TREATMENT OF CORNEAL PATHOLOGIES | June 2022 | December 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17830378 | LOW IRON HYDROUS PHOSPHOLIPID AND METHOD FOR SEPARATING LOW-IRON HYDROUS PHOSPHOLIPIDS FROM SOYBEAN OIL SEDIMENTS | June 2022 | August 2025 | Allow | 39 | 1 | 0 | No | No |
| 17779904 | INSULIN SECRETION-PROMOTING AGENT AND BLOOD SUGAR LEVEL IMPROVER USING SAME, DIABETES IMPROVER, AND FOOD | May 2022 | September 2025 | Allow | 40 | 1 | 0 | No | No |
| 17778786 | COMBINATION CANNABINOID-PHENYLETHANOID FORMULATION FOR TREATMENT OF INFLAMMATION AND METHODS RELATED THERETO | May 2022 | November 2025 | Allow | 42 | 1 | 0 | No | No |
| 17777897 | ACTIVE COMPOUND COMBINATIONS COMPRISING FATTY ACIDS | May 2022 | August 2025 | Allow | 39 | 1 | 0 | No | No |
| 17777402 | Processes for the Preparation of Alpha-Hydroxy Esters via Grignard Coupling and Thiolation Reactions | May 2022 | September 2025 | Allow | 40 | 2 | 0 | No | No |
| 17755498 | GUT-PROTECTIVE COMPOSITIONS COMPRISING BOSWELLIC ACID | April 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17771601 | SOLID STATE FORMS OF FEZAGEPRAS AND PROCESS FOR PREPARATION THEREOF | April 2022 | January 2026 | Allow | 45 | 1 | 0 | No | No |
| 17771139 | Compositions and Methods Related to Organic Oxides | April 2022 | October 2025 | Allow | 41 | 1 | 0 | No | No |
| 17765900 | METHOD OF PREPARATION WHITE EMULSIFIED SCENTED CROCODILE OIL | April 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17765986 | METHOD FOR PREPARING ALKENYL AMINOBORANES AND THEIR DERIVATIVES, AND USES THEREOF | April 2022 | December 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17763463 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SARCOPENIA CONTAINING NON-NATURAL AMINO ACID DERIVATIVE | March 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17762520 | PROCESS FOR THE DISTILLATION OF ISOCYANATES | March 2022 | September 2025 | Allow | 42 | 1 | 0 | No | No |
| 17760778 | SOLIDIFICATION OF HEXYL 2-[4-(DIETHYLAMINO)-2-HYDROXYBENZOYL]BENZOATE | March 2022 | August 2025 | Allow | 41 | 1 | 0 | No | No |
| 17753693 | PREVENTION OF MCPD FORMATION IN TRIACYLGLYCERIDE OILS | March 2022 | November 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17640419 | METHOD FOR PRODUCING ISOCYANATES | March 2022 | August 2025 | Allow | 42 | 1 | 0 | No | No |
| 17640024 | REACTOR TUBE ASSEMBLY | March 2022 | August 2025 | Allow | 41 | 1 | 0 | No | No |
| 17639751 | METHOD FOR PRODUCING HALOGENATED CARBONYL | March 2022 | July 2025 | Allow | 41 | 1 | 0 | No | No |
| 17637905 | METHOD FOR PRODUCING ISOCYANATE COMPOUND | February 2022 | February 2025 | Allow | 36 | 0 | 0 | No | No |
| 17673086 | Microemulsion Delivery Systems for Water-Based Beverages | February 2022 | November 2025 | Allow | 45 | 1 | 0 | No | No |
| 17619374 | Method Of Producing A Low Glycidol Monoglyceride Composition And The Low Glycidol Monoglyceride Composition As Such | December 2021 | November 2025 | Allow | 47 | 1 | 0 | No | No |
| 17611886 | FRAGRANCE OR FLAVOUR MIXTURE | November 2021 | January 2026 | Allow | 50 | 2 | 0 | No | No |
| 17518822 | BIOBASED GLYCERYL HEPTANOATE ESTER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | November 2021 | July 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17608720 | TREATMENT OF DIABETES | November 2021 | September 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17594776 | Pet Food Compositions Comprising Caprylic Acid and Docosahexaenoic Acid and/or Eicosapetaenoic Acid for Use in Treating Struvite Urolithiasis | October 2021 | July 2025 | Allow | 45 | 1 | 0 | No | No |
| 17607300 | EXTRACTING AND REFINING PLANT CUTICULAR WAXES FROM AQUEOUS DISPERSION USING TEMPERATURE AND PH ADJUSTMENT | October 2021 | November 2024 | Allow | 37 | 2 | 0 | No | No |
| 17594629 | COMPOSITION CONTAINING CREATINE FATTY ESTER FOR USE IN MEDICINE | October 2021 | May 2025 | Allow | 43 | 1 | 0 | No | No |
| 17601289 | VERY-LONG-CHAIN POLYUNSATURATED FATTY ACIDS, ELOVANOID HYDROXYLATED DERIVATIVES, AND METHODS OF USE | October 2021 | August 2025 | Allow | 47 | 1 | 0 | No | No |
| 17487047 | CRYSTALLINE FORM A OF 2, 2-BIS(4-FLUOROPHENYL)-2-PHENYLACETAMIDE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | September 2021 | December 2024 | Allow | 38 | 1 | 0 | No | No |
| 17441807 | NEAR-INFRARED-ABSORBING COMPOSITION, NEAR-INFRARED-ABSORBING FILM, AND IMAGE SENSOR FOR SOLID-STATE IMAGING ELEMENT | September 2021 | August 2025 | Allow | 47 | 1 | 0 | No | No |
| 17414559 | THERAPEUTIC, PREVENTIVE, OR IMPROVEMENT AGENT FOR INFLAMMATORY DISEASE AND ALLERGIC DISEASE | September 2021 | December 2024 | Allow | 42 | 1 | 0 | No | No |
| 17438548 | DALCETRAPIB IN THE TREATMENT OF SICKLE CELL TRAIT | September 2021 | August 2025 | Allow | 47 | 1 | 0 | No | No |
| 17428509 | LEVODOPA DERIVATIVE AND USE THEREOF | August 2021 | March 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17428327 | ACTIVE AGENTS FOR SKIN AND HAIR CARE WITH PHYSICOCHEMICAL MODIFYING PROPERTIES | August 2021 | December 2024 | Allow | 41 | 1 | 0 | No | No |
| 17427903 | Composition for Treatment and / or Prevention of Infectious Hoof Diseases | August 2021 | June 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17426319 | KETONE BODY PRODUCTION PROMOTING COMPOSITION | July 2021 | April 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17425746 | Topical Gel Compositions of Naproxen | July 2021 | December 2024 | Allow | 40 | 1 | 0 | No | No |
| 17309559 | CANNABINOID COMPOSITIONS WITH HIGH SOLUBILITY AND BIOAVAILABILITY | June 2021 | February 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17238345 | MODULAR, MOBILE, AND AUTOMATED SOLVENT EXTRACTION AND DISTILLATION SYSTEMS, AND METHODS OF USING THE SAME | April 2021 | February 2025 | Allow | 46 | 1 | 1 | No | No |
| 17282185 | THERAPEUTIC COMPOSITIONS | April 2021 | November 2024 | Allow | 44 | 1 | 1 | No | No |
| 17175601 | PROCESS SUPPORTED BY EQUIPMENT GROUP FOR EXTRACTING COMPOUNDS FROM BOTANICALS | February 2021 | January 2025 | Allow | 47 | 1 | 1 | No | No |
| 16968051 | EDIBLE OIL REFINING | August 2020 | June 2024 | Allow | 46 | 2 | 0 | No | No |
| 16843680 | METHOD AND APPARATUS FOR EXTRACTING BOTANICAL OILS | April 2020 | September 2025 | Abandon | 60 | 2 | 0 | No | Yes |
| 16606739 | THE NEW USE OF 2-[(3Z)-6-FLUORO-2-METHYL-3-[(4-METHYLSULFINYLPHENYL) METHYLIDENE]INDEN-1 -YL] ACETIC ACID | October 2019 | November 2025 | Allow | 60 | 9 | 0 | Yes | No |
| 16575125 | NAPHTHALENEDICARBOXYLIC ACID DICHLORIDE PRODUCTION METHOD | September 2019 | March 2020 | Allow | 6 | 0 | 0 | No | No |
| 16288353 | METHODS FOR REDUCING SOAP FORMATION DURING VEGETABLE OIL REFINING | February 2019 | January 2020 | Allow | 10 | 1 | 0 | No | No |
| 16329120 | METHOD FOR PREPARING SINGLE CRYSTAL OF ANHYDROUS HALOGENATED CHOLINE OR DERIVATIVE THEREOF | February 2019 | January 2020 | Allow | 10 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CARR, DEBORAH D.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 75.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CARR, DEBORAH D works in Art Unit 1691 and has examined 223 patent applications in our dataset. With an allowance rate of 96.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 19 months.
Examiner CARR, DEBORAH D's allowance rate of 96.0% places them in the 86% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by CARR, DEBORAH D receive 1.08 office actions before reaching final disposition. This places the examiner in the 11% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by CARR, DEBORAH D is 19 months. This places the examiner in the 94% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +4.1% benefit to allowance rate for applications examined by CARR, DEBORAH D. This interview benefit is in the 28% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 37.5% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 54.5% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 2% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 77.8% of appeals filed. This is in the 69% percentile among all examiners. Of these withdrawals, 57.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 41.0% are granted (fully or in part). This grant rate is in the 32% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 6.7% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.